Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
Type:
Application
Filed:
May 1, 2012
Publication date:
September 13, 2012
Applicant:
GENENTECH, INC.
Inventors:
LING-LING AN, SEK CHUNG FUNG, ROBERT F. KELLEY, HENRY B. LOWMAN, SANJAYA SINGH, HERREN WU
Abstract: A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP.
Abstract: The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Type:
Application
Filed:
October 12, 2011
Publication date:
September 13, 2012
Applicants:
Genentech, Inc., Array BioPharma Inc.
Inventors:
Ian S. MITCHELL, James F. BLAKE, Rui XU, Nicholas C. KALLAN, Dengming XIAO, Keith Lee SPENCER, Josef R. BENCSIK, Eli M. WALLACE, Stephen T. SCHLACHTER, Anna L. BANKA, Jun LIANG, Brian SAFINA, Birong ZHANG, Christine CHABOT, Steven DO
Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
Abstract: The present invention provides methods of using Bv8 and EG-VEGF polypeptides and nucleic acids to promote hematopoiesis. Also provided herein are methods of screening for modulators of Bv8 and EG-VEGF activity. Furthermore, methods of treatment using Bv8 and EG-VEGF polypeptides or Bv8 and EG-VEGF antagonists are provided.
Abstract: The invention relates to N-substituted azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to N-substituted azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
Type:
Grant
Filed:
June 11, 2008
Date of Patent:
September 4, 2012
Assignee:
Genentech, Inc.
Inventors:
Hazel Joan Dyke, Stephen Price, Karen Williams
Abstract: The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
Type:
Application
Filed:
March 15, 2012
Publication date:
August 23, 2012
Applicant:
Genentech, Inc.
Inventors:
Steven Staben, Jianwen Feng, Pui Leng Loke, Christian A.G.N. Montalbetti
Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
Type:
Application
Filed:
April 23, 2012
Publication date:
August 23, 2012
Applicant:
Genentech, Inc.
Inventors:
Kang Li, Bin-Bing Stephen Zhou, Wenjuan Wu, Sek Chung Fung, Sanjaya Singh
Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I): wherein Q, X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3?, R4, R4?, R5, R6, R6? and n are as described herein.
Type:
Grant
Filed:
December 19, 2006
Date of Patent:
August 21, 2012
Assignee:
Genentech, Inc.
Inventors:
Michael F. T. Koehler, Lewis Gazzard, Vickie Hsiao-Wei Tsui
Abstract: Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Type:
Grant
Filed:
September 10, 2008
Date of Patent:
August 21, 2012
Assignees:
Genentech, Inc., F. Hoffman-La Roche AG
Inventors:
Marcia Belvin, Lori Friedman, Klaus Hoeflich, Deepak Sampath, Ulka Vijapurkar, Jeffrey Wallin, Leisa Johnson, Mallika Singh, Sonal Patel
Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
Type:
Grant
Filed:
July 23, 2009
Date of Patent:
August 21, 2012
Assignees:
AC Immune S.A., Genentech, Inc.
Inventors:
Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
Abstract: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.
Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
Abstract: Methods for treating multiple sclerosis (MS) with a CD20 antibody using special dosing regimens and protocols are described. Articles of manufacture for use in such methods are also described.
Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4?, R5, R5?, R6 and R6? are as described herein.
Type:
Application
Filed:
January 23, 2012
Publication date:
August 9, 2012
Applicant:
Genentech, Inc.
Inventors:
Frederick Cohen, Kurt Deshayes, Wayne J. Fairbrother, Bainian Feng, John A. Flygare, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui
Abstract: Described herein are recombinant non-human cells and animals having an alteration of the S? region such that there is an elevated IgE level. Also described herein is an alteration in the IgH locus allows for enhanced class switch recombination (CSR) such that the desired heavy chain isotype is expressed at an elevated level relative to an unmodified cell.
Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.
Type:
Grant
Filed:
January 17, 2012
Date of Patent:
August 7, 2012
Assignee:
Genentech, Inc.
Inventors:
Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun